1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Nuo Therapeutics, Inc.

Nuo Therapeutics, Inc.

AURX
Nuo Therapeutics, Inc.US flagOther OTC
1.06
USD
-0.01
- -
51.31MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.11
0.06
0.09
- -
0.05
0.06
0.01
- -
- -
- -
0.01
0.03
- -
0.04
Basic EPS, GAAP
-0.2
-0.16
-0.42
- -
-1.02
-0.07
-0.05
0.31
- -
-0.08
-0.08
-0.05
- -
-0.05
Free Cash Flow per Basic Share
-0.12
-0.15
-0.12
- -
-0.33
-0.04
- -
- -
- -
-0.09
-0.08
-0.05
- -
-0.02
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.87
-0.91
-1.29
- -
-1.41
-0.95
-0.99
-0.92
-0.78
-0.67
-0.71
-0.71
- -
-0.72
Tangible Book Value per Share
-0.08
-0.12
-0.31
- -
0.03
- -
-0.02
-0.02
0.03
0.05
0.02
0.01
- -
-0.02
Basic Weighted Avg Shares
104
121
126
- -
15
23
24
26
30
40
42
45
- -
46
Sales/Revenue/Turnover
12
8
12
- -
1
1
- -
- -
- -
- -
1
1
3
2
Operating Margin (%)
-156.38
-241.01
-123.92
- -
-864.72
-109.78
-663.03
- -
- -
-2,958.21
-520.65
-180.04
-75.95
-133.5
Depreciation Expense
1
1
1
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-20
-19
-53
- -
-15
-2
-1
- -
- -
-3
-3
-2
-3
-2
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-174.99
-243.28
-458.76
- -
-2,077.36
-112.49
-817.43
- -
- -
-2,825.6
-521.17
-170.21
-75.82
-126.67
Working Capital
-1
13
-39
2
- -
- -
-1
-1
1
2
1
- -
- -
- -
LT Debt
4
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
Total Equity
27
16
-36
12
- -
- -
-1
-1
1
2
1
1
-1
-1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
47
47
47
Market Capitalization
63
55
70

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1
1
1
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
1
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-29.2%
-93.33%
-286.21%
Free Cash Flow
- -
813.01%
-52.24%
Net Income, GAAP
- -
675.85%
8.11%
Sales/Revenue/Turnover
- -
- -
142.72%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1
2025
- -
1
1
- -
3
2026
1
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
-0.01
-0.01
- -
-0.05
2025
-0.02
-0.01
- -
- -
- -
2026
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
David E. Jorden
Full Time Employees
9
Sector
Healthcare
Industry
Biotechnology
Address
8285 El Rio Houston TX United States of America 77054
IPO Date
Oct 24, 2017
CIK
0001091596
Website
nuot.com
Similar Companies
StemCell Institute Inc. (7096.T)
Recce Pharmaceuticals Ltd (RECEF)
Aspire Biopharma Holdings, Inc. (ASBP)
RegeneRx Biopharmaceuticals, Inc. (RGRX)
Ocumension Therapeutics (1477.HK)
Guangzhou Innogen Pharmaceutl Grp Co Ltd (2591.HK)
Business
Nuo Therapeutics, Inc. (AURX) operates as a commercial-stage medical device company that develops, commercializes and markets cell-based regenerative therapies harnessing the human body's innate healing capacity for chronic wound care primarily in the United States. The company offers its flagship Aurix System, a point-of-care biodynamic hematogel that processes a patient's autologous peripheral blood to produce platelet-rich plasma (PRP) gel containing growth factors such as VEGF, PDGF, EGF, FGF and TGF-β, along with antimicrobial peptides effective against pathogens including MRSA; Aurix targets chronic non-healing wounds including diabetic foot ulcers, venous leg ulcers, pressure injuries and surgically debrided wounds, serving hospital outpatient wound care clinics and private practice physicians. Founded in 1998 and headquartered at 8285 El Rio Street, Suite 190 in Houston, Texas, Nuo Therapeutics was formerly known as Cytomedix, Inc., changing its name in November 2014. In recent developments, the company entered a five-year exclusive private label distribution agreement with Smith+Nephew effective March 31, 2025, under which Smith+Nephew markets the Aurix System as the CENTRIO PRP system in the U.S. wound care market, providing Nuo with an annual upfront fee of approximately $1.3 million, minimum purchase commitments, and potential reimbursement milestone payments tied to Medicare code G0465 coverage. Additionally, Nuo announced a strategic partnership with PAM Health in April 2025 to expand access to the Aurix System across 23 states through PAM Health's clinical network, aiming to improve patient outcomes in chronic wound management. These alliances reflect Nuo's focus on scaling distribution and reimbursement in the advanced wound care sector projected to reach $17 billion by 2030.

Company News

APIChat

  • globenewswire.com

    Nuo Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

  • globenewswire.com

    Nuo Therapeutics Announces Exclusive Private Label Distribution Agreement with Smith+Nephew

  • globenewswire.com

    Nuo Therapeutics and PAM Health Partner to Advance Access to Regenerative Wound Healing Therapies